Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2011

Conditions
DepressionMajor Depression
Interventions
DRUG

TCAs, SSRIs, NARIs, SNRIs, Lithium

Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)

PROCEDURE

Electroconvulsive therapy

ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.

BEHAVIORAL

Cognitive behavioral group therapy

"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."

Trial Locations (1)

14050

Department of Psychiatry, Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany, Berlin

Sponsors
All Listed Sponsors
collaborator

German Research Foundation

OTHER

lead

Charite University, Berlin, Germany

OTHER